GPI are hiring! We are looking for innovative, team-orientated individuals to fill a number of open positions. Pricing Analyst – Data analyst from a pharma/health economics background PMA Consultant – Experienced consultant with solid background in project management and pricing strategies and/or modelling Innovation Lead – Head of Product Innovation where you will have overall responsibility … More GPI are hiring!
Canada’s plan to revise reference basket In a bid to reduce medicine prices in Canada, the Canadian Minister of Health announced the revision of the reference basket for international reference pricing (IRP). Medicines prices in Canada are regulated by the federal government, through the PMPRB (Patented Medicine Prices Review Board). The current reference rule used … More International Reference Pricing Reforms
With the largest population in the Middle East and North Africa region, Egypt has attracted a strong presence from multinational pharmaceutical companies. However, current turmoil over drug shortages and drug price hikes underscores the volatility of a market characterised by high out-of-pocket spending. Amid the economic instability that followed the 2011 Arab Spring, President Abdel-Fattah … More Egypt: Drug Price Hikes Highlight Market Volatility
Global Pricing Innovations (GPI) has strengthened its executive team with the addition of Alan Stewart. Alan joins GPI as Commercial Director to continue GPI’s success providing business services to valued clients across Europe and the US. GPI, the pricing experts, has strengthened its executive team this week with the addition of Alan Stewart. Alan joins … More Global Pricing Innovations is pleased to announce the addition of Alan Stewart to the executive team
By Preeti Patel and Sophie Schmitz on Oct 3, 2016 We analyze recent changes in Germany’s pharmaceutical legislation & implications for the industry. Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial opportunities and has an important position as an international reference country to … More AMNOG and the German Reforms: What Will Change?
Pati Ladron – Client Solutions Lead at GPI Published 6th July 2016 The Chinese government launched a healthcare … More China Drug Pricing Reforms – Potential Impact of IRP?
Brexit: in or out? If you have lived in the UK for the past year, or anywhere else in the world for that matter, you are probably very familiar with the term. As one of the biggest political decisions of the 21st century, much confusion and concern has been brewing across industries with pharma being … More BREXIT: Is the pharmaceutical industry at risk?